<DOC>
	<DOCNO>NCT00811902</DOCNO>
	<brief_summary>The primary objective ass activity nerispirdine improve ability walk , patient multiple sclerosis ( MS ) . Secondary objective : - To assess measure walk ability , tiredness , low limb muscular strength , spasticity , clinical assessment subject clinical assessment change Study Investigator - To assess safety tolerance nerispirdine - To evaluate pharmacokinetics ( PK ) parameter nerispirdine</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Nerispirdine Patients With Multiple Sclerosis</brief_title>
	<detailed_description>Total duration per patient approximately 19 week total , comprise 3-week screening period inclusive 2-week placebo run-in period , 14-week treatment period , 2-week placebo run-out ( follow-up ) period</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Clinically definite MS ( accord McDonald criterion ) , Multiple sclerosis exacerbation clinical relapse within 6month prior screen visit . Subject able complete two trial time 25 foot walk , without assist device , Patients without valid V1 , V2 , V4 T25FW measurement eligible randomization . Female patient either pregnant breastfeeding . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
</DOC>